A US judge has dismissed Bayer's plea to halt Johnson & Johnson's advertising for its prostate cancer drug Erleada. Bayer alleged false claims about a halved death risk compared to its own drug, Nubeqa. The court found J&J's campaign accurately reflected its study's findings, deeming Bayer's arguments insufficient for an injunction. Bayer vows to pursue the case on its merits.